Leo I. Gordon, MD

Leo I. Gordon, MD, discusses toxicities associated with lisocabtagene maraleucel in patients with mantle cell lymphoma.

Leo I. Gordon, MD, discusses the clinical implications of findings from the mantle cell lymphoma cohort of the TRANSCEND NHL 001 trial evaluating liso-cel.

Leo I. Gordon, MD, discusses future steps for optimizing the use of lisocabtagene maraleucel in the treatment of relapsed/refractory mantle cell lymphoma.

Leo I. Gordon, MD, discusses the evolution of the treatment paradigm in relapsed/refractory mantle cell lymphoma.

Leo I. Gordon, MD, discusses the significance of the FDA approval of liso-cel for patients with relapsed/refractory mantle cell lymphoma.

Shared excitement for bispecific antibodies and other promising novel therapies in the treatment of patients with DLBCL.

A look at exciting investigational agents and clinical trials for patients with relapsed/refractory diffuse large B-cell lymphoma.

The panelists share their approach to the treatment and work-up of patients who require salvage therapy.

Experts in lymphoma take part in a discussion on supportive care for patients who receive CAR T-cell therapy.

Subject matter experts in lymphoma reflect on chimeric antigen receptor T-cell therapy clinical trial design.

Frederick Locke, MD, provides an in-depth look at data from 3 clinical trials investigating chimeric antigen receptor T-cell therapy in the second-line treatment of diffuse large B-cell lymphoma.

Optimizing approaches to therapeutic sequencing in relapsed/refractory DLBCL.

Drs Nowakowski and Gordon discuss treatment options after disease relapse on CAR T-cell therapy.

Physicians speculate on the potential impact of bispecific antibodies on the treatment landscape of DLBCL.

The panelists discuss the importance of using real-world evidence in addition to data from clinical trials to inform decision-making.

Oncologists discuss the efficacy and safety of a tafasitamab plus lenalidomide for relapsed/refractory DLBCL and share personal experiences relevant to its use.

Caron Jacobson, MD, and Matthew Lunning, DO, FACP, assess the available treatment options for patients with R/R DLBCL.

Drs Locke and Gordon explain how outcomes for patients with DLBCL have improved as treatments continue to evolve.

Experts in lymphoma discuss how they risk stratify patients and the currently available options for first-line diffuse large-b cell lymphoma treatment.

Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor of medicine (hematology and oncology), Northwestern University Feinberg School of Medicine, discussed emerging chemotherapy-free regimens in the treatment of patients with follicular lymphoma.

Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, Northwestern University Feinberg School of Medicine, discusses the use of checkpoint inhibitors in the treatment of patients with Hodgkin lymphoma.

Leo I. Gordon, MD, a professor of medicine at Feinberg School of Medicine, Northwestern University, discusses clinical trials in Hodgkin lymphoma.

Leo I. Gordon, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the role of checkpoint inhibitors for patients with hematologic malignancies.

Leo I. Gordon, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, discusses the concerns of chimeric antigen receptor (CAR) T-cell therapy.